Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2024-10-17 Capital/Financing Update
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issuance of Commercial Papers by Mankind Pharma Limited. It includes detailed disclosures about the Commercial Papers such as face value, tenure, allotment and maturity dates, coupon rates, and other terms. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating it is a regulatory announcement. The content focuses on financing activities, specifically the issuance of debt instruments (Commercial Papers). The document length is 2937 characters, which is relatively short and primarily an announcement rather than a detailed financial report. Therefore, this fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-10-17 English
Allotment of Securities
Capital/Financing Update Classification · 100% confidence The document is a formal announcement dated October 16, 2024, addressed to stock exchanges regarding the allotment of Non-Convertible Debentures (NCDs) by Mankind Pharma Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the issuance of NCDs including number, face value, total amount, tenure, coupon rates, and security charges. The document is primarily an update on the company's financing activity, specifically the allotment of debt instruments. It does not contain comprehensive financial statements or detailed financial performance analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory certification or a report publication announcement. The content fits the category of Capital/Financing Update (CAP) as it provides detailed information on the company's fundraising through debt issuance.
2024-10-16 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialization/rematerialization of shares for the quarter ended September 30, 2024. It is a compliance certificate from the Registrar and Share Transfer Agent to the company secretary. The document is short (2097 characters) and primarily an attestation letter rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a regulatory compliance certificate rather than a full report or announcement of financial results or corporate actions.
2024-10-09 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a notification to stock exchanges regarding an update on a proposed acquisition transaction. It references prior announcements and regulatory approvals obtained for the acquisition of 100% stake in Bharat Serums and Vaccines Limited. The content is an update on a financing/transaction activity rather than a full report, financial statements, or meeting materials. It does not contain financial results, management discussion, or voting results. The document fits the category of Capital/Financing Update (CAP) as it provides information on the progress of a significant acquisition transaction and regulatory approvals related to it.
2024-10-02 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the completion of a business transfer (Over the Counter Business Undertaking) on a slump sale basis to a wholly owned subsidiary. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events. The document is short (1431 characters) and serves as an update or announcement rather than a detailed report or financial statement. There is no financial data, no detailed analysis, no management discussion, or audit information. It is clearly an announcement of a corporate event related to a transaction but not a merger filing or detailed M&A document. Given the nature of the content and the regulatory reference, this fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including transfer of business units or assets on a slump sale basis.
2024-09-30 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a notification under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the assignment and reaffirmation of credit ratings by ICRA Limited for various financial instruments of the company. It is an update on credit rating status, which relates to financing and capital structure information. The document is short (1813 characters) and serves as an intimation rather than a detailed report or financial statement. Therefore, it fits best under Capital/Financing Update (CAP).
2024-09-30 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.